Renaissance Capital logo

CytoMed Therapeutics Priced, Nasdaq: GDTC

Singaporean preclinical biotech developing gamma-delta T cell therapies for cancer.

Industry: Health Care

Latest Trade: $2.18 -0.02 (-0.9%)

First Day Return: 0.0%

Return from IPO: -45.0%

Industry: Health Care

We are a pre-clinical biopharmaceutical company focused on harnessing our proprietary technologies into creating novel cell-based immunotherapies for treatment of human cancers. The development of our novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into treatment of solid tumors. We believe that the current development of CD19-targeting CAR-T cells in treating B-cell malignancies signifies that cellular immunotherapy is becoming one of the pillars in cancer care. Built on the proprietary platform technologies that we licensed, we are developing three product candidates: CTM-N2D, iPSC-gdNKT and CTM-GDT. CTM-N2D is our lead product candidate and it consists of expanded gamma delta T cells grafted with NKG2DL-targeting CAR to enhance anti-cancer cytotoxicity.
more less
IPO Data
IPO File Date 11/18/2022
Offer Price $4.00
Price Range $4.00 - $5.00
Offer Shares (mm) 2.4
Deal Size ($mm) $10
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 04/13/2023
Offer Price $4.00
Price Range $4.00 - $5.00
Offer Shares (mm) 2.4
Deal Size ($mm) $10
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
The Benchmark Company
Axiom Capital Management
Company Data
Headquarters Singapore
Founded 2018
Employees at IPO 25
Website www.cytomed.sg

CytoMed Therapeutics (GDTC) Performance